A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Public ClinicalTrials.gov record NCT05306574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Study identification
- NCT ID
- NCT05306574
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2022
- Primary completion
- Jan 5, 2025
- Completion
- Jan 5, 2025
- Last update posted
- Jan 8, 2026
2022 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Anniston, Alabama Site | Anniston | Alabama | 36207 | — |
| Mission Hills Site | Mission Hills | California | 91345 | — |
| Orange Site | Orange | California | 92868 | — |
| Thousands Oaks Site | Thousand Oaks | California | 91360 | — |
| Miami, FL Site | Miami | Florida | 33014 | — |
| Tampa, Florida Site | Tampa | Florida | 33765 | — |
| Wheaton, Maryland Site | Wheaton | Maryland | 20902 | — |
| Grand Blanc Site | Grand Blanc | Michigan | 48439 | — |
| Baytown Site | Baytown | Texas | 77521 | — |
| Colleyville, Texas Site | Colleyville | Texas | 76034 | — |
| Houston Site | Houston | Texas | 77084 | — |
| Waco Site | Waco | Texas | 76710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05306574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05306574 live on ClinicalTrials.gov.